Medtronic Posts Higher-Than-Expected Q3 Profits
Medtronic Plc, which recently completed the $49.9 billion acquisition of Ireland-based Covidien Plc, posted better-than-expected third-quarter profits, driven by solid growth in its cardiac and vascular business.
The company’s heart devices including implantable defibrillators, artificial valves and devices to treat atrial fibrillation, an irregular rhythm, contributed to a 5 percent increase in sales in the cardiac and vascular business, its largest unit. Excluding the impact of the strong U.S. dollar, sales in the division were up 10 percent.
Medtronic acquired Covidien to expand the range of products it can offer to hospitals, lower its global tax burden and improve access to its cash outside the United States.
It forecast revenue growth of 4 percent to 6 percent for the combined company in the fourth quarter ending in April. If the dollar remains at its current foreign exchange rate, the impact would be a $420 million to $480 million reduction in reported fourth-quarter revenue, Chief Financial Officer Gary Ellis said on a conference call. Ellis said that the company would project revenue growth in the mid-single-digit range for fiscal 2016, on a constant-currency basis.
In the third quarter ended Jan. 23, Medtronic’s net profit rose to $977 million, from $762 million a year earlier.
Excluding charges primarily for the Covidien acquisition, Medtronic earned $1.01 per share, above the average analyst estimate of 97 cents according to Thomson Reuters I/B/E/S.
Third-quarter revenue increased to $4.32 billion from $4.16 billion. Analysts were expecting $4.25 billion. U.S. revenue rose 8 percent to $2.46 billion. International revenue fell 2 percent to $1.86 billion, hit by the stronger dollar. Excluding the dollar’s impact, international sales increased 7 percent.
Source: Reuters.com
Related Articles
-
Medtronic will invest up to $75 million and immediately begin co-promotion of CathWorks’ FFRangio System for the noninvasive diagnosis of CAD in the U.S., Europe and Japan, where it is commercially available.
-
An analysis of the HVAD pump implant kit showed moisture had entered the center post of the pump causing corrosion and demagnetization of the internal magnets, which may cause the pump to rotate incorrectly.
-
The catheter is part of the company’s transcatheter pulmonary valve system.
-
“This cutting-edge technology empowers us with the ability to navigate complex vascular procedures with greater precision, ensuring optimal outcomes for our patients. We are honored to be a part of this innovative program.”
